Montpellier University Hospital
Montpellier, Hérault, 34295, France
NCT Number: NCT03838549
Implant-based reconstruction is currently the most common choice for mastectomy reconstruction. Whatever the choice of mastectomy incision, a scar remains on or near the breast volume. Current techniques involve partial or total coverage of the implant with the pectoralis major muscle, to prevent exposure or infection. The muscle dissection technique applied has functional and cosmetic consequences. In this study, an endoscopic approach will be evaluated. This new surgical technique, using a single-port endoscopic way, will put the scar is in the axillary area, away from the breast. The hypothesis is that this delocalized scar potentially reduces the risk of exposure and allows placement of the implant in the subcutaneous space, with no manipulation of the pectoralis major muscle.
Looking for future studies?
Notify Me20 year and older
Female
Interventional
Not applicable
Montpellier, Hérault, 34295, France
It s a practicability study, evaluating endoscopic approach for prophylactic mastectomy, using an axillary single port. Classic open surgery conversion rate, operative time, infectious rate, esthetical outcomes, and functional outcomes will be evaluated.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
It is an endoscopic approach for prophylactic mastectomy using an axillary single port
Time frame: one day
The total mastectomy is done by a scar in the axillary area, away from the breast, using single port endoscopy, with Implant base reconstruction in pre pectoral position.
Complete excision of the gland by means of an incision on the axillary line, Installation of a definitive smooth prosthesis, Absence of conversion to a conventional approach, No skin necrosis
Time frame: one day
Duration of the prophylactic mastectomy with immediate breast reconstruction
Time frame: one day
Open surgery conversion rate
Time frame: 1 and 3 months after the prophylactic mastectomy
Number of participants with early postoperative infection two months after the prophylactic mastectomy
Time frame: one day
Blood loss (milliliters) during the prophylactic mastectomy with immediate breast reconstruction
Time frame: Between the day of the prophylactic mastectomy and a month later
Number of participants with a local haematoma caused by the prophylactic mastectomy with immediate breast reconstruction
Time frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
Number of patients with disunity of the scar after the prophylactic mastectomy
Time frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
Number of patients with the prothesis exposed after the prophylactic mastectomy
Time frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
Number of patients with seromas after the prophylactic mastectomy
Time frame: 3 and 12 months after the prophylactic mastectomy
Refractory induced hypercapnia: EtCO2 (expired fraction of CO2)> 45mmHg and refractory to ventilation ; second degree secondary burn
Time frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
The presence of skin case necrosis will be noted during all the visits after the surgery. It's severe if > 25%
Time frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
The presence of necrosis of areolo-nipple plaque will be noted during all the visits after the surgery.
Time frame: 1, 3, 6 and 12 months after the prophylactic mastectomy
The level of pain of the operated breasts will be self-assessed by the patient with EVA at 1, 3, 6, 12 months after the surgery. EVA is mesured between 0 and 10 (0: no pain ; 10: extremely intense pain)
Time frame: Through discharge from hospitalization, an average of 7 days
The duration of hospitalization will be noted upon discharge from hospitalization
Time frame: 3 and 12 months after the prophylactic mastectomy
BREAST-Q© questionnaire Version 2.0 measure the quality of life and satisfaction among patients undergoing breast surgery. This questionnaire includes 6 modules: 1) Augmentation module, 2) Reduction/Mastectomy module, 3) Breast cancer: a) Mastectomy module, b) Reconstruction module, c) Breast reconstruction expectations module, d) Breast conserving therapy module.
The conceptual framework of the modules is comprised of following two overarching themes (or domains): 1) Health-related quality of life and 2) Patient satisfaction. 1) Under each of these domains, there are six subthemes; Quality of life: 1) Psychosocial, 2) Physical and 3) Sexual well-being; and Patient satisfaction: 4) Satisfaction with Breasts, 5) Satisfaction with Outcome and 6) Satisfaction with care.
Cf. https://qportfolio.org/wp-content/uploads/2020/BREAST-Q-USERS-GUIDE-V2.pdf for the response options.
Time frame: 3 and 12 months after the prophylactic mastectomy
the need to use one or more lipomodelages
Time frame: 3 months after the prophylactic mastectomy
Evaluation of the Constant score by a physiotherapist from the gynecology Department. The Constant score includes 5 items: Pain [0;5], Daily activity level [0;10], Level of work with the hand [0;10], Mobility [0;40] and Muscular force [0;25].
The Constant score is mesured between 0 and 100. The higher the score, the fewer problems there are for the patient, 100 is the ideal score.
Time frame: 3 and 12 months after the prophylactic mastectomy
Quality of life with an european quality of life scale (EQ-5D-3L). The EQ-5D-3L descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).
University Hospital, Montpellier
Other
Acronym: MRIMOP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06484725
Breast Cancer, Breast Diseases
Milan, MI, Italy
View Trial DetailsNCT05771454
BRCA Mutation, Breast Cancer
Karachi, Sindh, Pakistan
View Trial DetailsNCT01346761
Adnexal Diseases, Breast Cancer
Salt Lake City, Utah, United States
View Trial DetailsNCT05736497
Disease Attributes, Disease Susceptibility
Philadelphia, Pennsylvania, United States
View Trial Details